Tafenoquine paediatric

GSK

Legend
Product vision
  • Product targeting prevention of relapse for P. vivax
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
  • Tafenoquine
Dosing
  • Single-dose treatment in children who cannot take the adult tablet
  • Final dose regimen/weight banding to be confirmed based on paediatric study final analysis
Efficacy

  • Efficacy in adults established. Pharmacokinetic bridging strategy to establish paediatric dose
Key features
  • Single-dose treatment to prevent relapse of P. vivax malaria
  • Contraindicated in G6PD deficiency
Challenges

  • Quantitative testing for G6PD deficiency required

  • Clarity around continued role for primaquine (G6PD-deficient patients)
Status

  • Paediatric pharmacokinetics bridging study recruitment was completed October 2019
Next milestone

  • Paediatric pharmacokinetics bridging study readout
MMV Project Director

  • Dr Isabelle Borghini